Dergiler / Turkish Journal of Urology / 2016 / Cilt: 42 - Sayı: 4

Diagnostic value of microRNAs in prostate cancer patients with prostate specific antigen (PSA) levels between 2, and 10 ng/mL

Sayfa
247–255
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

It was thought that diagnostic role of miRNAs in the early diagnosis of the different stages of PCa needed to be examined in further studies with larger groups

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Prostate specific antigen (PSA), used for the early diagnosis of prostate cancer (PCa), is one of the best tumour markers known so far.
📊
Temel Bulgular & Veri:However, in situations when PSA is between 2-10 ng/mL, which is named as grey zone, PSA falls short of distinguishing benign prostate diseases from PCa.
💡
Sonuç & Katkı:It was thought that diagnostic role of miRNAs in the early diagnosis of the different stages of PCa needed to be examined in further studies with larger groups
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Prostate specific antigen (PSA), used for the early diagnosis of prostate cancer (PCa), is one of the best tumour markers known so far. However, in situations when PSA is between 2-10 ng/mL, which is named as grey zone, PSA falls short of distinguishing benign prostate diseases from PCa. On the other hand, it was demonstrated in many previous studies that microRNA (miRNA) could be a marker for cancer. Therefore, in this study, it was aimed to enhance the diagnostic power of PSA, especially with grey zone patients, by the use of miRNA.Material and Methods: Ninety-four patients included in the study were divided into three groups as “control group” (n=44, PSA=2-10 ng/mL and benign), “PCa 1 group” (n=37, PSA=2-10 ng/mL), and “PCa 2 group” (n=13, PSA >10 ng/mL), according to their pathological results and PSA levels. Free PSA (fPSA) and total PSA (T-PSA) levels were measured with chemiluminometric sandwich immunoassay method. Expressions of miRNAs were analyzed using quantitative reverse transcription-polymerase chain reaction (qRTPCR) method. The most appropriate specificity, sensitivity and prediction values were found by drawing the receiver operating characteristic (ROC) curves of total PSA, free/total PSA (f/T PSA) ratio, and miRNAs, and the diagnostic powers were compared with each other.Results: Diagnostic powers of the f/T PSA ratio and miRNA were compared in PCa 1 and the control groups to determine the marker with higher area under the curve (AUC). It was shown that the diagnostic power of the combination of miR-16-5p and f/T PSA was higher than that obtained when they were used separately.Conclusion: As a result, while making the the discrimination between benign and malignant prostate in patients with grey zone, it was determined that the combination of miR-16-5p and f/T PSA was more valuable than T-PSA or f/T PSA alone. It was thought that diagnostic role of miRNAs in the early diagnosis of the different stages of PCa needed to be examined in further studies with larger groups

🔖

Bu Makaleye Atıf Yap

AKBAYIR, S., MUŞLU, N., ERDEN, S., BOZLU, M. (2016). Diagnostic value of microRNAs in prostate cancer patients with prostate specific antigen (PSA) levels between 2, and 10 ng/mL. Turkish Journal of Urology, Cilt: 42 - Sayı: 4, 247–255. https://ajindex.com/articles/379724

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer Clin 2016
  2. [CrossRef] 2. Grönberg H. Prostate cancer epidemiology. Lancet 2003
  3. [CrossRef] 3. Reiter RE, deKernion JB. Epidemiology, Etiology, and Prevention of Prostate Cancer. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds). Campbell’s Urology, Volume 4. 8th ed. Philadelphia, London New York, St. Louis, Sydney, Toronto. Saunders 2002
  4. Aydin S, Boz MY. Rapid changes in the incidence of urinary cancers in Turkey. Turk J Urol 2015
  5. [CrossRef] 5. Smith RA, Mettlin CJ, Davis KJ, Eyre H. American Cancer Society Guidelines for the early detection of cancer. CA Cancer J Clin 2000
  6. [CrossRef] 6. Carroll P, Coley C, McLeod D, Schellhammer P, Sweat G, Wasson J, et al. Prostate specific antigen best practice policy. Part I. Early detection and diagnosis of prostate cancer. Urology 2001
  7. [CrossRef] 7. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6630 men. J Urol 1994
  8. Alkibay T, Gürocak S. Tümör immünolojisi ve tümör belirleyiciler. Anafarta K, Bedük Y, Arıkan N. Temel Üroloji. 3. Baskı. Ankara: Öncü Basımevi, 2007. p. 687-98. 9. Deliveliotis C, Alivizatos G, Stavropoulos N, Makrychoritis K, Koutsokalis G, Kiriakakis Z, et al. Influence of digital examination, cystoscopy, transrectal ultrasonography and needle biopsy on the concentration of prostate specific antigen. Urol Int 1994
  9. [CrossRef] 10. Jackson RJ, Standart N. How do microRNAs regulate gene expression? Sci STKE 2007
  10. re1. [CrossRef] 11. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993
  11. [CrossRef] 12. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: Contributions of translational repression and mRNA decay. Nat Rev Genet 2011
  12. [CrossRef] 13. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004
  13. [CrossRef] 14. Kong W, Zhao JJ, He L, Cheng JQ. Strategies for profiling microRNA expression. J Cell Physiol 2009
  14. [CrossRef] 15. Blenkiron C, Miska EA. miRNAs in cancer: approache